Radnostix, Inc. reported fiscal‑year 2025 revenue of $13.07 million, a 6 % decline from the $13.90 million earned in 2024, and a net loss of $908,002 versus a $8,574 profit in the prior year. The revenue drop was driven by weaker performance in the Theranostics and Cobalt Products segments, while the Calibration & Reference Products line grew 21 % and the Medical Devices segment saw modest gains, partially offsetting the overall decline.
Gross profit fell to $7.70 million, down 11 % from $8.65 million in 2024, and the gross‑profit margin contracted from 62 % to 59 %. The decline reflects a shift in sales mix toward lower‑margin products and higher operating expenses, including costs associated with NRC enforcement matters and medical‑device buildout.
The company had previously projected a $10.2 million net cash inflow from the sale of its non‑core Fluorine Products assets, which was intended to provide a 12‑18 month runway. However, the Asset Purchase Agreement with American Fuel Resources was mutually terminated on March 11 2026, and Radnostix retained the assets. Consequently, the expected cash inflow and runway did not materialize.
CEO Shahe Bagerdjian said, "With the resurgence in large scale nuclear energy projects, including several domestic uranium enrichment initiatives, we believe these assets have meaningful value to our shareholders and the fuel cycle industry as a whole." He added, "I want to thank AFR for their persistence and efforts in trying to close this deal and their transparency at the end. We look forward to exploring all our options for the DUF6 assets over the coming months."
The company’s segment performance highlights a mixed picture: Calibration & Reference Products grew 21 % driven by new PET‑focused products and recovery from Co‑57 shortages; Medical Devices saw modest growth; Theranostics and Cobalt Products declined due to supply outages and customer demand shifts. No analyst coverage or market reaction data were reported, and the company did not disclose guidance for the next fiscal year in this release.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.